Last reviewed · How we verify
NCT07476534
Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression
trial in Solid Tumor Malignancies in 100 participants. Not yet recruiting.
1 September 2026
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xinxiang Medical College |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 March 2026 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 December 2026 |
Conditions studied
- Solid Tumor Malignancies — all drugs for Solid Tumor Malignancies →
Sponsor
The First Affiliated Hospital of Xinxiang Medical College
Who can join
18 and older, any sex, with Solid Tumor Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Identifying and validating molecular biomarkers associated with tumor-related anxiety and depression. By integrating psychological assessment data from clinical tumor patients with molecular detection results, and utilizing clinically accessible samples such as tumor tissues and sera from clinical cohorts, this study aims to clinically validate the tumor-derived proteins previously identified by our team as having potential regulatory roles. The goal is to clarify the clinical value of tumor-derived proteins as molecular biomarkers for tumor-related anxiety and depression, providing a molecular basis for early screening and risk stratification. Alternatively, it seeks to establish a tumor-related anxiety and depression risk assessment model based on the expression levels of tumor-derived proteins, offering a reference for the precise identification and targeted intervention of psychological disorders in tumor patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07476534
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor Malignancies
Currently open trials in the same condition.
- NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
- NCT07231120 — A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy · Phase 1 · recruiting
- NCT07167381 — xDRIVE for Florida-based Cancer Patients · NA · recruiting
- NCT07174453 — Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies · Phase 3 · recruiting
- NCT07181473 — A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors · Phase 1 · recruiting
Other The First Affiliated Hospital of Xinxiang Medical College trials
Trials by the same sponsor.
- NCT07530016 — Clinical Efficacy and Mechanisms of a Topical Azone-Tranexamic Acid-Aloe Polysaccharide Gel in the Treatment of Melasma · NA · not yet recruiting
- NCT07530003 — HUMSCs Combined With Col I to Third-Degree Burn Wound · Phase 1, PHASE2 · recruiting
- NCT07347496 — A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined · Phase 4 · not yet recruiting
- NCT07376577 — Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP · NA · not yet recruiting
- NCT07325123 — Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07476534 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xinxiang Medical College
- Last refreshed: 17 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07476534.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing